Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Plasma long-chain free fatty acids predict mammalian longevity

  • Naudí i Farré, Alba
  • Jové Font, Mariona
  • Aledo, Juan Carlos
  • Ayala Jové, Ma. Victoria (Maria Victoria)
  • Cabré Cucó, Rosanna
  • Portero Otín, Manuel
  • Barja, Gustavo
  • Pamplona Gras, Reinald
determination of their longevity. In the present work, the use of high-throughput technologies allowed us to determine the plasma lipidomic profile of 11 mammalian species ranging in maximum longevity from 3.5 to 120 years. The non-targeted approach revealed a specie-specific lipidomic profile that accurately predicts the animal longevity. The regression analysis between lipid species and longevity demonstrated that the longer the longevity of a species, the lower is its plasma long-chain free fatty acid (LC-FFA) concentrations, peroxidizability index, and lipid peroxidation-derived products content. The inverse association between longevity and LC-FFA persisted after correction for body mass and phylogenetic interdependence. These results indicate that the lipidomic signature is an optimized feature associated with animal longevity, emerging LC-FFA as a potential biomarker of longevity, We acknowledge funding from the Spanish Ministry of Science and Innovation (CGL2010-18124) to J.C.A.; from the Spanish Ministry of Health (PI11-01532) to M.P.O.; and from the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI), the Generalitat of Catalonia (2009SGR735), and the La MaratoTV3 Foundation to R.P. R.C. was supported by a Generalitat of Catalonia Predoctoral Fellowship. We thank David Argiles for excellent technical assistance. We thank Dr. Montserrat Rué for her support in statistical analyses.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Lifelong treatment with atenolol decreases membrane fatty acid unsaturation and oxidative stress in heart and skeletal muscle mitochondria and improves immunity and behaviour, without changing mice longevity.

  • Pamplona Gras, Reinald
  • Portero Otín, Manuel
  • Naudí i Farré, Alba
  • Fuente, Monica de la
  • Barja, Gustavo
  • López Torres, Mónica
  • Mate, Ianire
  • Cruces, Julia
  • Gómez, José
  • Sánchez-Roman, Ines
  • Gómez Rodríguez, Alexia
The membrane fatty acid unsaturation hypothesis of aging and longevity is experimentally tested for the first time in mammals. Lifelong treatment of mice with the b1-blocker atenolol increased the amount of the extracellular-signal-regulated kinase signaling protein and successfully decreased one of the two traits appropriately correlating with animal longevity, the membrane fatty acid unsaturation degree of cardiac and skeletal muscle mitochondria, changing their lipid profile toward that present in much more longer-lived mammals. This was mainly due to decreases in 22:6n-3 and increases in 18:1n-9 fatty acids. The atenolol treatment also lowered visceral adiposity (by 24%), decreased mitochondrial protein oxidative, glycoxidative, and lipoxidative damage in both organs, and lowered oxidative damage in heart mitochondrial DNA. Atenolol also improved various immune (chemotaxis and natural killer activities) and behavioral functions (equilibrium, motor coordination, and muscular vigor). It also totally or partially prevented the aging-related detrimental changes observed in mitochondrial membrane unsaturation, protein oxidative modifications, and immune and behavioral functions, without changing longevity. The controls reached 3.93 years of age, a substantially higher maximum longevity than the best previously described for this strain (3.0 years). Side effects of the drug could have masked a likely lowering of the endogenous aging rate induced by the decrease in membrane fatty acid unsaturation. Weconclude that it is atenolol that failed to increase longevity, and likely not the decrease in membrane unsaturation induced by the drug., This investigation was supported by I + D grants from the Spanish Ministry of Science and Innovation (BFU2011-23888 to G.Barja); UCMGroups of Research (910379ENEROINN), BFU2011-30336, and RETICEF (RD 12/0043/0018) from ISCIII-FEDER of the European Union to M. De la Fuente; Spanish Ministry of Health (PI11/01532) to M.Portero Otin; and Spanish Ministry of Science and Innovation (BFU2009-11879) and the Generalitat of Catalonia (2009SGR735) to R. Pamplona.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Plasma long-chain free fatty acids predict mammalian longevity

  • Naudí i Farré, Alba
  • Jové Font, Mariona
  • Aledo, Juan Carlos
  • Ayala Jové, Ma. Victoria (Maria Victoria)
  • Cabré Cucó, Rosanna
  • Portero Otín, Manuel
  • Barja, Gustavo
  • Pamplona Gras, Reinald
determination of their longevity. In the present work, the use of high-throughput technologies allowed us to determine the plasma lipidomic profile of 11 mammalian species ranging in maximum longevity from 3.5 to 120 years. The non-targeted approach revealed a specie-specific lipidomic profile that accurately predicts the animal longevity. The regression analysis between lipid species and longevity demonstrated that the longer the longevity of a species, the lower is its plasma long-chain free fatty acid (LC-FFA) concentrations, peroxidizability index, and lipid peroxidation-derived products content. The inverse association between longevity and LC-FFA persisted after correction for body mass and phylogenetic interdependence. These results indicate that the lipidomic signature is an optimized feature associated with animal longevity, emerging LC-FFA as a potential biomarker of longevity, We acknowledge funding from the Spanish Ministry of Science and Innovation (CGL2010-18124) to J.C.A.; from the Spanish Ministry of Health (PI11-01532) to M.P.O.; and from the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI), the Generalitat of Catalonia (2009SGR735), and the La MaratoTV3 Foundation to R.P. R.C. was supported by a Generalitat of Catalonia Predoctoral Fellowship. We thank David Argiles for excellent technical assistance. We thank Dr. Montserrat Rué for her support in statistical analyses.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lifelong treatment with atenolol decreases membrane fatty acid unsaturation and oxidative stress in heart and skeletal muscle mitochondria and improves immunity and behaviour, without changing mice longevity.

  • Pamplona Gras, Reinald
  • Portero Otín, Manuel
  • Naudí i Farré, Alba
  • Fuente, Monica de la
  • Barja, Gustavo
  • López Torres, Mónica
  • Mate, Ianire
  • Cruces, Julia
  • Gómez, José
  • Sánchez-Roman, Ines
  • Gómez Rodríguez, Alexia
The membrane fatty acid unsaturation hypothesis of aging and longevity is experimentally tested for the first time in mammals. Lifelong treatment of mice with the b1-blocker atenolol increased the amount of the extracellular-signal-regulated kinase signaling protein and successfully decreased one of the two traits appropriately correlating with animal longevity, the membrane fatty acid unsaturation degree of cardiac and skeletal muscle mitochondria, changing their lipid profile toward that present in much more longer-lived mammals. This was mainly due to decreases in 22:6n-3 and increases in 18:1n-9 fatty acids. The atenolol treatment also lowered visceral adiposity (by 24%), decreased mitochondrial protein oxidative, glycoxidative, and lipoxidative damage in both organs, and lowered oxidative damage in heart mitochondrial DNA. Atenolol also improved various immune (chemotaxis and natural killer activities) and behavioral functions (equilibrium, motor coordination, and muscular vigor). It also totally or partially prevented the aging-related detrimental changes observed in mitochondrial membrane unsaturation, protein oxidative modifications, and immune and behavioral functions, without changing longevity. The controls reached 3.93 years of age, a substantially higher maximum longevity than the best previously described for this strain (3.0 years). Side effects of the drug could have masked a likely lowering of the endogenous aging rate induced by the decrease in membrane fatty acid unsaturation. Weconclude that it is atenolol that failed to increase longevity, and likely not the decrease in membrane unsaturation induced by the drug., This investigation was supported by I + D grants from the Spanish Ministry of Science and Innovation (BFU2011-23888 to G.Barja); UCMGroups of Research (910379ENEROINN), BFU2011-30336, and RETICEF (RD 12/0043/0018) from ISCIII-FEDER of the European Union to M. De la Fuente; Spanish Ministry of Health (PI11/01532) to M.Portero Otin; and Spanish Ministry of Science and Innovation (BFU2009-11879) and the Generalitat of Catalonia (2009SGR735) to R. Pamplona.